In 2010, Sigma Pharmaceutical restructured and sold its generic drug manufacturing business to South Africa’s Aspen Pharmacare for AUD$804 million, ending an almost 100-year legacy in the manufacturing field for the company.
In 2010, Sigma Pharmaceutical underwent a restructuring and sold its generic drug manufacturing operations to South Africa's Aspen Pharmacare for AUD$804 million, ending a nearly 100-year history in the manufacturing sector for the company.